Loading asset research
Intensity Therapeutics Inc. Common stock
INTSNasdaq · USD · StocksQuote as of · Exchange session not verified$4.02
-0.50%
Today
INTS
Loading 1D prices…
Market cap
$13.1M
Volume
10.5K
52w high
$43.5052w low
$3.51Company profile
Intensity Therapeutics Inc. Common stock
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
Shelton, CT, United States
Employees
5
Fiscal year end
1231
CIK
1567264
Session & valuation
Open$4.10
Previous close$4.04
Day high$4.12
Day low$3.98
30-day avg. volume31.8K
Outstanding shares3.3M
Diluted EPS-$8.56
Latest annual period
P/E (trailing)-0.47
P/E (forward)-2.02
Price / book1.29
Beta3.03
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| PLURPluri Inc. Common Stock | $14.6M | $1M | -2344.59% | -$2.44 | -5.60% | Unrated |
| PASGPassage Bio Inc. Common Stock | $16.1M | $0.00 | — | -$14.35 | +0.30% | Hold |
| INABIN8bio Inc. Common Stock | $10.5M | $0.00 | — | -$4.44 | -2.73% | Buy |
| BCDABioCardia Inc. Common Stock | $16.3M | $0.00 | — | -$1.23 | -1.82% | Buy |
| GRMLGreenland Mines Ltd. Common Stock | $10M | $0.00 | — | -$0.22 | -17.67% | Unrated |